Company profile
Abivax S.A.
NASDAQ:ABVXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ABX-196 | phase1_2 | — | 1 | active |
| OBEFAZIMOD | phase3 | — | 18 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02990325 | phase1_2 | completed | 2017-03-27 | 2018-12-27 | Abivax S.A. | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults |
| NCT05535946 | phase3 | active_not_recruiting | 2023-01-16 | 2026-04-28 | Abivax S.A. | ABTECT - Maintenance |
| NCT05507203 | phase3 | completed | 2022-10-10 | 2025-06-24 | Abivax S.A. | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
| NCT05507216 | phase3 | completed | 2022-12-21 | 2025-06-24 | Abivax S.A. | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 |
| NCT03897543 | phase1_2 | recruiting | 2019-08-30 | 2021-06-30 | Abivax S.A. | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma |
FDA applications (0)
No records yet.